Posted by Michael Wonder on 18 Oct 2019
PHARMAC publishes draft agenda for November 2019 PTAC meeting
18 October 2019 - Eight agenda items; not one new medicine/product.
The PTAC is set to consider the following medicines:
- Multiple (listed) medicines for multiple sclerosis - widening access criteria (nothing new here)
- Cladribine - multiple sclerosis (new use for an old medicine)
- Sirolimus - widening of access to include lymphovascular malformations (new use for an old medicine)
- mTOR inhibitors - renal angiomyolipoma and refractory seizures associated with tuberous sclerosis complex (nothing new here)
- TNF alfa inhibitors - amendment of criteria for juvenile idiopathic arthritis (nothing new here)
- Tacrolimus suppository – rectal inflammation (new formulation of an old medicine)
- Adalimumab & infliximab - drug monitoring Inflammatory bowel disease (nothing new here)
- Adalimumab - ulcerative colitis (new use for an old medicine)
Read PTAC agenda
Posted by:
Michael Wonder